

Mass General Brigham IRB Mass General Brigham

399 Revolution Drive, Suite 710 Somerville, MA 02145

Tel: 857-282-1900 Fax: 857-282-5693

## **Notification of IRB Review**

Protocol #: 2021P002615

October 05, 2021 [Reissued October 19, 2021] Date:

Sarpatwari, Ameet, Ph.D, JD To:

BWH

Mass General Brigham > BWH > Medicine > Pharmacoepidemiology

From: Mass General Brigham IRB

399 Revolution Drive, Suite 710

Somerville, MA 02145

Title of Protocol: Risk Evaluation and Mitigation Strategy (REMS) Programs to

Promote Appropriate Medication Use and Knowledge: Physician

Interviews on Experiences with REMS Programs

Version/Number: Detailed Protocol-V1

09/08/2021 Version Date:

Sponsor/Funding/Support Proposal Risk evaluation and mitigation strategy (REMS)

Title: programs to promote appropriate medication use and

knowledge

Principal

Sarpatwari, Ameet

Investigator:

**Immediate** Sponsor:

Food & Drug Administration (Contracts)

Award

75F40120C00044 Number:

Fund #: 123748

IRB Review Type: Expedited IRB Approval Date: 10/05/2021

**Next Review:** Exempt Check In

**IRB Expiration Date:** 10/05/2024 IRB Review Action: Exempt

The IRB has determined that this project meets the criteria for exemption 45 CFR 46.104(d)(#).

EXEMPTION (2) Research that only includes interactions involving educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures, or observation of public behavior (including visual or auditory recording) if at least ONE of the following criteria is met:



## Mass General Brigham IRB

Mass General Brigham 399 Revolution Drive, Suite 710 Somerville, MA 02145

Tel: 857-282-1900 Fax: 857-282-5693

- (i) The information obtained is recorded by the investigator in such a manner that the identity of the human subjects cannot readily be ascertained, directly or through identifiers linked to the subjects;
- (ii) Any disclosure of the human subjects' responses outside the research would not reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, educational advancement, or reputation; or

## **ANCILLARY COMMITTEES**

1. Nursing (BWH): Approved

2. MCA (MGB): Review not needed

As Principal Investigator, you are responsible for the following:

- 1. Ensuring that this project is conducted in compliance with the exemption determination.
- 2. Ensuring that all study staff have completed the required human research education requirements through the Collaborative Institutional Training Initiative (CITI).
- 3. Submission of significant proposed changes to this project to ensure that the project continues to meet the criteria for exemption.
- 4. Submission of Exempt Check-In as required by institutional policy.

Questions related to this project may be directed to IRB@partners.org

cc:

Ameet Sarpatwari, Ph.D, JD, Principal Investigator, Pharmacoepidemiology, Medicine